<DOC>
	<DOCNO>NCT01053143</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity one dose A/H1N1 non-adjuvanted pandemic vaccine support registration vaccine India . Primary Objective : - To describe safety profile ( injection site reaction systemic event ) vaccine within 21 day follow vaccination , serious adverse event throughout study subject Secondary Objectives : - To describe immune response vaccine 21 day vaccination hemagglutination inhibition ( HAI ) test subject - To describe antibody persistence 6 month vaccination HAI test subject .</brief_summary>
	<brief_title>Study Swine-Origin A/H1N1 Influenza Non-Adjuvanted Vaccine Healthy Adults India</brief_title>
	<detailed_description>Each study participant receive one dose study vaccine Day 0 , provide pre- post-vaccination blood sample 21 180 day immunogenicity test undergo safety follow-up 6 month post-vaccination .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Inclusion Criteria : 18 year age day inclusion Provision inform consent form sign participant . If participant illiterate , independent witness require sign consent form . Participant able attend schedule visit comply trial procedure For female , sexually active , use effective method contraception abstinence least 4 week prior first vaccination , least 4 week last vaccination . Exclusion Criteria : Participation another clinical trial investigate vaccine , drug , medical device , medical procedure 4 week precede trial vaccination Planned participation another clinical trial present trial period Receipt vaccine 4 week precede trial vaccination Planned receipt vaccine study period ( except 6 month follow ) Receipt blood bloodderived product past 3 month , might interfere assessment immune response Known suspect congenital acquired immunodeficiency ; receipt immunosuppressive therapy anticancer chemotherapy radiation therapy within precede 6 month ; longterm systemic corticosteroid therapy ( prednisone equivalent 2 consecutive week within past 3 month ) Known seropositivity human immunodeficiency virus , hepatitis B , hepatitis C report participant / parent legal representative and/or base medical history Known systemic hypersensitivity vaccine component , history lifethreatening reaction vaccine ( ) use trial vaccine contain substance Known thrombocytopenia , contraindicate intramuscular vaccination Bleeding disorder , receipt anticoagulant 3 week precede inclusion , contraindicate intramuscular vaccination Deprived freedom administrative court order , emergency setting , hospitalize involuntarily Chronic illness , opinion Investigator , stage might interfere trial conduct completion Employee Investigator study center , direct involvement propose study study direction Investigator study center , well family member employee Investigator Previous participation trial investigate vaccine swineorigin A/H1N1 influenza strain History influenza infection 20092010 Receipt allergy shot and/or seasonal allergy medication 7day period prior enrollment ( vaccination ) , schedule receive allergy shot and/or seasonal allergy medication 7day period enrollment ( vaccination ) Known pregnancy , positive urine pregnancy Currently breastfeed child Current alcohol abuse drug addiction might interfere ability comply trial procedure Temporary contraindication resolve vaccination : Febrile illness ( temperature ≥38.0°C ) moderate severe acute illness/infection day vaccination .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Influenza</keyword>
	<keyword>Pandemic Influenza</keyword>
	<keyword>Swine-Origin Influenza A/H1N1 Non-adjuvanted Vaccine</keyword>
	<keyword>Influenza A Virus , H1N1 subtype</keyword>
	<keyword>Adults</keyword>
</DOC>